GTC
RNAC icon

Ghost Tree Capital’s Cartesian Therapeutics RNAC Stock Holding History

Ghost Tree Capital’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-33,333
Closed -$2.84M – 55
2020
Q2 		$2.84M Sell
33,333
-24,167
-42% -$2.19M 0.75% 35
2020
Q1 		$4.16M Buy
57,500
+19,167
+50% +$1.85M 1.1% 20
2019
Q4 		$2.74M Buy
+38,333
New +$1.85M 0.52% 42

Other funds holding RNAC

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Ghost Tree Capital's RNAC Position: Q3 2020 in Review

Ghost Tree Capital sold out of Cartesian Therapeutics (RNAC) in Q3 2020, closing a stake of 33,333 shares — an estimated $2.84M sold.

Ghost Tree Capital first reported a position in RNAC in Q4 2019 and held it in 3 quarters. The position peaked at $4.16M in Q1 2020. 79 funds tracked by Wall St. Rank hold RNAC as of Q3 2020.

  • Ghost Tree Capital reported no remaining Cartesian Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Ghost Tree Capital sold 33,333 Cartesian Therapeutics shares in Q3 2020, an estimated $2.84M.
  • Ghost Tree Capital first reported a position in Cartesian Therapeutics in Q4 2019 and held it in 3 quarters.
  • Ghost Tree Capital's Cartesian Therapeutics position peaked at $4.16M in Q1 2020.
  • 79 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2020.

Based on Ghost Tree Capital's 13F filing for Q3 2020, filed 16 Nov 2020.